Published in PLoS One on February 17, 2011
TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov (2014) 1.19
A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics (2014) 0.91
Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med (2014) 0.79
Cooperation of tyrosine kinase receptor TrkB and epidermal growth factor receptor signaling enhances migration and dispersal of lung tumor cells. PLoS One (2014) 0.78
Linkage analysis of extended high-risk pedigrees replicates a cutaneous malignant melanoma predisposition locus on chromosome 9q21. J Invest Dermatol (2012) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Cancer genes and the pathways they control. Nat Med (2004) 24.22
The cancer genome. Nature (2009) 23.13
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Oncogenic kinase signalling. Nature (2001) 16.30
Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem (2003) 8.83
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Targeted cancer therapy. Nature (2004) 7.81
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53
Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet (1998) 3.41
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Persistent use of "false" cell lines. Int J Cancer (2008) 2.01
Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci (1996) 1.97
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol (2009) 1.74
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 1.64
Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res (2007) 1.56
Characterization of an epithelioid cell line derived from rat small intestine: demonstration of cytokeratin filaments. Cell Biol Int Rep (1984) 1.38
Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res (1997) 1.36
Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res (1980) 1.31
The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci (2006) 1.25
Selective labeling of neurotransmitter transporters at the cell surface. Methods Enzymol (1998) 1.23
Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res (2005) 1.22
TrkA glycosylation regulates receptor localization and activity. J Neurobiol (1999) 1.17
The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res (2005) 1.07
TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res (2009) 1.02
TrkB variants with deletions in the leucine-rich motifs of the extracellular domain. J Biol Chem (1997) 0.91
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 bind to a single leucine-rich motif of TrkB. Biochemistry (1995) 0.89
Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr Med Chem (1999) 0.83
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
The essence of senescence. Genes Dev (2010) 8.21
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer (2006) 4.14
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature (2007) 3.26
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 2.63
Metastasis mechanisms. Biochim Biophys Acta (2009) 2.51
Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol (2008) 2.30
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest (2012) 2.03
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol (2009) 1.74
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol (2011) 1.61
E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59
Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res (2007) 1.56
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem (2005) 1.33
Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A (2014) 1.30
Deregulating EMT and senescence: double impact by a single twist. Cancer Cell (2008) 1.29
Tumor type-dependent function of the par3 polarity protein in skin tumorigenesis. Cancer Cell (2012) 1.28
PRIME importance of pathology expertise. Nat Biotechnol (2009) 1.19
Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med (2014) 1.17
Dual Role of alpha6beta4 integrin in epidermal tumor growth: tumor-suppressive versus tumor-promoting function. Mol Biol Cell (2007) 1.16
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature (2012) 1.08
The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res (2005) 1.07
Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res (2009) 1.05
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem (2005) 1.04
Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) (2010) 1.03
Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood (2009) 1.02
Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res (2013) 1.02
Loss of integrin α3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells. Proc Natl Acad Sci U S A (2012) 1.02
An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res (2006) 0.96
Impact papers on aging in 2009. Aging (Albany NY) (2010) 0.89
Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol (2013) 0.89
Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis (2009) 0.85
Evidence of oncogene-induced senescence in thyroid carcinogenesis. Endocr Relat Cancer (2011) 0.84
Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell Melanoma Res (2015) 0.83
SUMOylation of DRIL1 directs its transcriptional activity towards leukocyte lineage-specific genes. PLoS One (2009) 0.83
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res (2015) 0.83
Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J (2011) 0.82
Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents. Breast Cancer Res Treat (2013) 0.80
Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency. Leuk Res (2007) 0.80
GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors. PLoS One (2012) 0.79
Ageing: Old cells under attack. Nature (2011) 0.79
Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells. Proc Natl Acad Sci U S A (2013) 0.79
Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma. Pigment Cell Melanoma Res (2014) 0.79
Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood (2007) 0.78
Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". J Invest Dermatol (2008) 0.78
Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Sci Rep (2013) 0.77
Regulation of neurons in the suprachiasmatic nucleus of Xenopus laevis. Comp Biochem Physiol B Biochem Mol Biol (2002) 0.76
Interrogating open issues in cancer medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.75
If you can't beat me, join me: collaborating oncogenes circumventing senescence and causing cancer. Pigment Cell Melanoma Res (2011) 0.75
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Cancer Lett (2009) 0.75